Anti-obesity agent Acomplia is withdrawn

The marketing authorisation for Acomplia (rimonabant) has been suspended after a European Medicines Agency (EMEA) review.

The EMEA's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Acomplia no longer outweigh its risks and that the marketing authorisation should be suspended across the EU.

The CHMP considered that new data from post-marketing experience and ongoing clinical trials indicated that serious psychiatric disorders may be more common than in the clinical trials used in the initial assessment of the medicine. The CHMP was also of the opinion that these psychiatric side-effects could not be adequately addressed by further risk minimisation measures.

Prescribers should not issue any prescriptions for Acomplia and should review the treatment of patients currently taking the medication. There is no need for patients to stop treatment with Acomplia immediately, but patients who wish to stop can do so at any time.

Further information: EMEA Q&A on recommendation to suspend Acomplia

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases